PECAM1 and breast carcinoma: Surprisingly, the endothelial marker CD31/PECAM1 showed no relationship to survival in melanoma or breast cancer patients, while CD105/ENDOGLIN mRNA expression correlated negatively with the number of days until death in melanoma patients (Fig. 2I).